A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides pteronyssinus) in patients with controlled allergic bronchial asthma + rhinitis/rhinoconjunctivitis.

Trial Profile

A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides pteronyssinus) in patients with controlled allergic bronchial asthma + rhinitis/rhinoconjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 13 Apr 2013 Planned end date 1 Feb 2015 added as reported by European Clinical Trials Database.
    • 21 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top